Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Targeting human telomerase for cancer therapeutics.

Guittat L, Alberti P, Gomez D, De Cian A, Pennarun G, Lemarteleur T, Belmokhtar C, Paterski R, Morjani H, Trentesaux C, Mandine E, Boussin F, Mailliet P, Lacroix L, Riou JF, Mergny JL.

Cytotechnology. 2004 Jun;45(1-2):75-90. doi: 10.1007/s10616-004-5127-z.

2.

Role of ATM in the telomere response to the G-quadruplex ligand 360A.

Pennarun G, Granotier C, Hoffschir F, Mandine E, Biard D, Gauthier LR, Boussin FD.

Nucleic Acids Res. 2008 Mar;36(5):1741-54. doi: 10.1093/nar/gkn026. Epub 2008 Feb 7.

3.

Preferential binding of a G-quadruplex ligand to human chromosome ends.

Granotier C, Pennarun G, Riou L, Hoffschir F, Gauthier LR, De Cian A, Gomez D, Mandine E, Riou JF, Mergny JL, Mailliet P, Dutrillaux B, Boussin FD.

Nucleic Acids Res. 2005 Jul 28;33(13):4182-90. Print 2005.

4.

Apoptosis related to telomere instability and cell cycle alterations in human glioma cells treated by new highly selective G-quadruplex ligands.

Pennarun G, Granotier C, Gauthier LR, Gomez D, Hoffschir F, Mandine E, Riou JF, Mergny JL, Mailliet P, Boussin FD.

Oncogene. 2005 Apr 21;24(18):2917-28.

PMID:
15735722
5.

Stabilization of the c-myc gene promoter quadruplex by specific ligands' inhibitors of telomerase.

Lemarteleur T, Gomez D, Paterski R, Mandine E, Mailliet P, Riou JF.

Biochem Biophys Res Commun. 2004 Oct 22;323(3):802-8.

PMID:
15381071
6.

Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.

Lange G, Lesuisse D, Deprez P, Schoot B, Loenze P, Bénard D, Marquette JP, Broto P, Sarubbi E, Mandine E.

J Med Chem. 2003 Nov 20;46(24):5184-95.

PMID:
14613321
7.

High-affinity Src-SH2 ligands which do not activate Tyr(527)-phosphorylated Src in an experimental in vivo system.

Mandine E, Jean-Baptiste V, Vayssière B, Gofflo D, Bénard D, Sarubbi E, Deprez P, Baron R, Superti-Furga G, Lesuisse D.

Biochem Biophys Res Commun. 2002 Oct 25;298(2):185-92.

PMID:
12387813
8.

Principles governing the binding of a class of non-peptidic inhibitors to the SH2 domain of src studied by X-ray analysis.

Lange G, Lesuisse D, Deprez P, Schoot B, Loenze P, Bénard D, Marquette JP, Broto P, Sarubbi E, Mandine E.

J Med Chem. 2002 Jul 4;45(14):2915-22.

PMID:
12086479
9.

SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2.

Lesuisse D, Lange G, Deprez P, Bénard D, Schoot B, Delettre G, Marquette JP, Broto P, Jean-Baptiste V, Bichet P, Sarubbi E, Mandine E.

J Med Chem. 2002 Jun 6;45(12):2379-87.

PMID:
12036348
10.

Small ligands interacting with the phosphotyrosine binding pocket of the Src SH2 protein.

Deprez P, Mandine E, Gofflo D, Meunier S, Lesuisse D.

Bioorg Med Chem Lett. 2002 May 6;12(9):1295-8.

PMID:
11965374
11.

Discovery of highly potent Src SH2 binders: structure-activity studies and X-ray structures.

Deprez P, Baholet I, Burlet S, Lange G, Amengual R, Schoot B, Vermond A, Mandine E, Lesuisse D.

Bioorg Med Chem Lett. 2002 May 6;12(9):1291-4.

PMID:
11965373
12.

Imidazole-based ligands of the Src SH2 protein.

Deprez P, Mandine E, Vermond A, Lesuisse D.

Bioorg Med Chem Lett. 2002 May 6;12(9):1287-9.

PMID:
11965372
13.

Discovery of thioazepinone ligands for Src SH2: from non-specific to specific binding.

Lesuisse D, Deprez P, Albert E, Duc TT, Sortais B, Gofflo D, Jean-Baptiste V, Marquette J, Schoot B, Sarubbi E, Lange G, Broto P, Mandine E.

Bioorg Med Chem Lett. 2001 Aug 20;11(16):2127-31.

PMID:
11514153
14.

Src homology-2 domain binding assays by scintillation proximity and surface plasmon resonance.

Mandine E, Gofflo D, Jean-Baptiste V, Sarubbi E, Touyer G, Deprez P, Lesuisse D.

J Mol Recognit. 2001 Jul-Aug;14(4):254-60.

PMID:
11500972
15.

Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption.

Violette SM, Guan W, Bartlett C, Smith JA, Bardelay C, Antoine E, Rickles RJ, Mandine E, van Schravendijk MR, Adams SE, Lynch BA, Shakespeare WC, Yang M, Jacobsen VA, Takeuchi CS, Macek KJ, Bohacek RS, Dalgarno DC, Weigele M, Lesuisse D, Sawyer TK, Baron R.

Bone. 2001 Jan;28(1):54-64.

PMID:
11165943
16.

Inhibition of production of tumor necrosis factor by monoclonal antibodies to lipopolysaccharides.

Vacheron F, Mandine E, Lenaour R, Smets P, Zalisz R, Guenounou M.

J Infect Dis. 1992 May;165(5):873-8.

PMID:
1569336
17.

Toxicity and activity of purified trichosanthin.

Ferrari P, Trabaud MA, Rommain M, Mandine E, Zalisz R, Desgranges C, Smets P.

AIDS. 1991 Jul;5(7):865-70.

PMID:
1892592
18.
19.

Supplemental Content

Loading ...
Support Center